IMAGENEBIO INC
IMANASDAQTrading Snapshot
- Day Range
- $4.53 – $4.66
- 52-Week Range
- $3.94 – $9.10
- Volume
- $2.70B
- Avg Volume
- $2.60B
- Shares Outstanding
- 11.3M
- Next Earnings
- Nov 17, 2026
Fundamentals Snapshot
- Annual Revenue
- $800,000
- Last Q Revenue
- $184,753
- P/E Ratio
- —
- P/S Ratio
- 5.7x
- EPS (TTM)
- $-5.34
- Dividend Yield
- —
- Dilution (1yr)
- +693.1%
Why Investors Own IMA
- ✓High-growth profile — revenue up +30.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 70% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
IMAGENEBIO INC
IMA
StockOtter · stockotter.spaceAbout IMAGENEBIO INC
ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will participate in a fireside chat at the H.C
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on August 14, 2026, the Compensation Committee of the Company's Board of Directors (the “Compe
ImageneBio Reports Second Quarter 2026 Financial Results
SAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("Imagene" or the "Company") today reported financial results for the quarter ended June 30, 2026, and provided a company update. Company Highli
ImageneBio Appoints Matt Robbins as General Counsel
Brings more than 15 years of corporate, securities, and transactional experience advising public and private life sciences companies Brings more than 15 years of corporate, securities, and transactional experience advisi